GlassScriptPhysician profile
Paula Young
NPI 1831659861
$3,988.47
in general payments reported to CMS, 2019-2025
21 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $457 · 2023: $2,481 · 2024: $722 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,387 · Education: $26.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,386.76 |
| Education | $26.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,133.99 | 2022-2025 | |
| Daiichi Sankyo INC. | $597.63 | 2021-2024 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $391.72 | 2022-2024 | Xifaxan, Trulance, Plenvu |
| Pfizer INC. | $269.74 | 2022-2024 | |
| Janssen Biotech, INC. | $238.47 | 2022-2024 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $226.71 | 2022-2024 | Entyvio, Gattex |
| Gilead Sciences, INC. | $166.40 | 2024-2025 | |
| Amgen INC. | $162.63 | 2023 | Avsola, Amjevita |
| Celgene Corporation | $144.08 | 2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $104.17 | 2022-2024 | Linzess |
| Alexion Pharmaceuticals, INC. | $99.02 | 2023 | |
| Nestle Healthcare Nutrition INC. | $95.94 | 2022-2023 | |
| Organon LLC | $77.91 | 2024-2025 | Nexplanon |
| Viiv Healthcare Company | $54.11 | 2024-2025 | Apretude |
| Braintree Laboratories, INC. | $48.76 | 2022-2023 | Sutab |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $46.73 | 2023 | Rebyota, Clenpiq |
| Merck Sharp & Dohme LLC | $41.70 | 2024 | Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.00 | 2023 | Cyltezo |
| Si-Bone, INC. | $20.97 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.24 | 2025 | Rexulti |
| Intercept Pharmaceuticals, INC. | $17.55 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.